CN108348515A - 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 - Google Patents

咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 Download PDF

Info

Publication number
CN108348515A
CN108348515A CN201680063635.3A CN201680063635A CN108348515A CN 108348515 A CN108348515 A CN 108348515A CN 201680063635 A CN201680063635 A CN 201680063635A CN 108348515 A CN108348515 A CN 108348515A
Authority
CN
China
Prior art keywords
methyl
dimethylamino
quinoline
imidazo
pyridyl groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063635.3A
Other languages
English (en)
Chinese (zh)
Inventor
K.G.派克
B.C.巴拉姆
T.A.亨特
A.J.伊瑟顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN108348515A publication Critical patent/CN108348515A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680063635.3A 2015-11-05 2016-11-02 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途 Pending CN108348515A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1519568.8A GB201519568D0 (en) 2015-11-05 2015-11-05 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
GB1519568.8 2015-11-05
PCT/EP2016/076416 WO2017076898A1 (en) 2015-11-05 2016-11-02 Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Publications (1)

Publication Number Publication Date
CN108348515A true CN108348515A (zh) 2018-07-31

Family

ID=55132360

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063635.3A Pending CN108348515A (zh) 2015-11-05 2016-11-02 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途

Country Status (22)

Country Link
US (1) US20180280377A1 (cg-RX-API-DMAC7.html)
EP (1) EP3370722A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019501873A (cg-RX-API-DMAC7.html)
KR (1) KR20180073684A (cg-RX-API-DMAC7.html)
CN (1) CN108348515A (cg-RX-API-DMAC7.html)
AU (1) AU2016348620B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018007811A2 (cg-RX-API-DMAC7.html)
CA (1) CA3002717A1 (cg-RX-API-DMAC7.html)
CL (1) CL2018001171A1 (cg-RX-API-DMAC7.html)
CO (1) CO2018004933A2 (cg-RX-API-DMAC7.html)
CR (1) CR20180308A (cg-RX-API-DMAC7.html)
DO (1) DOP2018000115A (cg-RX-API-DMAC7.html)
GB (1) GB201519568D0 (cg-RX-API-DMAC7.html)
HK (1) HK1257677A1 (cg-RX-API-DMAC7.html)
IL (1) IL258828A (cg-RX-API-DMAC7.html)
MX (1) MX2018004954A (cg-RX-API-DMAC7.html)
NI (1) NI201800051A (cg-RX-API-DMAC7.html)
PE (1) PE20181346A1 (cg-RX-API-DMAC7.html)
PH (1) PH12018500957A1 (cg-RX-API-DMAC7.html)
RU (1) RU2018120492A (cg-RX-API-DMAC7.html)
SV (1) SV2018005680A (cg-RX-API-DMAC7.html)
WO (1) WO2017076898A1 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020063855A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN114258301A (zh) * 2019-07-30 2022-03-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2026130110A1 (zh) * 2024-12-16 2026-06-25 北京富龙康泰生物技术有限公司 咪唑酮类化合物、及其药物组合物和用途

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN111344293A (zh) 2017-09-20 2020-06-26 阿斯利康(瑞典)有限公司 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
CN110386932A (zh) * 2018-04-20 2019-10-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2019201283A1 (en) 2018-04-20 2019-10-24 Xrad Therapeutics, Inc. Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2020052688A1 (en) * 2018-09-14 2020-03-19 Suzhou Zanrong Pharma Limited 1-ISOPROPYL-3-METHYL-8- (PYRIDIN-3-YL) -1, 3-DIHYDRO-2H-IMIDAZO [4, 5-c] CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOF
WO2021098734A1 (zh) * 2019-11-19 2021-05-27 南京明德新药研发有限公司 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用
CN116194109A (zh) 2020-06-24 2023-05-30 阿斯利康(英国)有限公司 抗体-药物缀合物和atm抑制剂的组合
CN116056698B (zh) * 2020-09-21 2024-11-19 威尚(上海)生物医药有限公司 具有血脑屏障穿透能力的取代的1-(3,3-二氟哌啶-4-基)-咪唑并[4,5-c]喹啉-2-酮化合物
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
WO2010139731A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
CN102372711A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CA2242425C (en) 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN102399218A (zh) 2010-09-16 2012-04-04 和记黄埔医药(上海)有限公司 一类并合三杂环及其作为pi3k抑制剂的用途
NO2714752T3 (cg-RX-API-DMAC7.html) * 2014-05-08 2018-04-21

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103636A1 (en) * 2007-02-20 2008-08-28 Novartis Ag Imidazoquinolines as dual lipid kinase and mtor inhibitors
WO2010139731A1 (en) * 2009-06-04 2010-12-09 Novartis Ag 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
CN102372711A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 咪唑并喹啉类PI3K和mTOR双重抑制剂

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020063855A1 (zh) * 2018-09-30 2020-04-02 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
CN112771045A (zh) * 2018-09-30 2021-05-07 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
US11230549B2 (en) 2018-09-30 2022-01-25 Medshine Discovery Inc. Quinolino-pyrrolidin-2-one derivative and application thereof
CN112771045B (zh) * 2018-09-30 2022-04-19 南京明德新药研发有限公司 喹啉并吡咯烷-2-酮类衍生物及其应用
CN114258301A (zh) * 2019-07-30 2022-03-29 艾科思莱德制药公司 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂
WO2021197339A1 (zh) * 2020-03-30 2021-10-07 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
CN115380031A (zh) * 2020-03-30 2022-11-22 南京明德新药研发有限公司 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用
WO2026130110A1 (zh) * 2024-12-16 2026-06-25 北京富龙康泰生物技术有限公司 咪唑酮类化合物、及其药物组合物和用途

Also Published As

Publication number Publication date
HK1257677A1 (zh) 2019-10-25
NI201800051A (es) 2018-07-30
CL2018001171A1 (es) 2018-10-12
SV2018005680A (es) 2018-06-22
RU2018120492A (ru) 2019-12-05
BR112018007811A2 (en) 2018-10-30
PE20181346A1 (es) 2018-08-22
CO2018004933A2 (es) 2018-08-10
AU2016348620B2 (en) 2019-05-02
US20180280377A1 (en) 2018-10-04
WO2017076898A1 (en) 2017-05-11
MX2018004954A (es) 2018-07-06
CR20180308A (es) 2018-10-02
EP3370722A1 (en) 2018-09-12
IL258828A (en) 2018-06-28
GB201519568D0 (en) 2015-12-23
CA3002717A1 (en) 2017-05-11
AU2016348620A1 (en) 2018-06-14
KR20180073684A (ko) 2018-07-02
RU2018120492A3 (cg-RX-API-DMAC7.html) 2020-01-30
DOP2018000115A (es) 2018-06-30
JP2019501873A (ja) 2019-01-24
PH12018500957A1 (en) 2018-11-19

Similar Documents

Publication Publication Date Title
HK1257677A1 (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
TWI662034B (zh) 咪唑并[4,5-c]喹啉-2-酮化合物及其治療癌症之用途
CN108349971A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它们在治疗癌症中的用途
CN108137576B (zh) 8-[6-[3-(氨基)丙氧基]-3-吡啶基]-1-异丙基-咪唑并[4,5-c]喹啉-2-酮衍生物
TW201837045A (zh) 胺基-三唑并吡啶化合物及其在治療癌症中之用途
TW202035410A (zh) 嘌呤酮化合物及其在治療癌症中之用途
TW201808948A (zh) 咪唑并[4,5-c]喹啉-2-酮化合物以及它們在治療癌症中之用途
CN111344293A (zh) 1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
KR20230157467A (ko) 모세혈관 확장성 운동실조증 돌연변이(atm) 키나아제의 선택적 조절제 및 이의 용도
BR112016025153B1 (pt) &#34;compostos de imidazo[4,5-c]quinolin-2-ona, composição farmaceutica e seu uso no tratamento de câncer
HK1232528A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
HK1232528B (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1257677

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1257677

Country of ref document: HK